Lovastatin - Revision history

Alexander Berchansky at 12:43, 10 January 2024

Alexander Berchansky — Wed, 10 Jan 2024 12:43:43 GMT

←Older revision		Revision as of 12:43, 10 January 2024
Line 1:		Line 1:
-	<~~applet~~ load="" size=~~"[450,380]" color="" frame="true" spin="on" Scene ="Lovastatin/Lovastatin/1" align~~="right" caption="Lovastatin, also known as Mevacor"/>	+	<StructureSection load='' size='340' side='right' caption='Lovastatin, also known as Mevacor' scene='Lovastatin/Lovastatin/1'>
	===Better Known as: Mevacor===		===Better Known as: Mevacor===
	* Marketed By: Merck & Co. <br />		* Marketed By: Merck & Co. <br />
Line 11:		Line 11:
	===Mechanism of Action===		===Mechanism of Action===
	Lovastatin is rapidly hydrolyzed in vivo into its corresponding b-hydroxyacid, which is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>		Lovastatin is rapidly hydrolyzed in vivo into its corresponding b-hydroxyacid, which is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
-		+	</StructureSection>
	===Pharmacokinetics===		===Pharmacokinetics===
	<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">		<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">

David Canner at 08:58, 10 December 2010

David Canner — Fri, 10 Dec 2010 08:58:59 GMT

←Older revision		Revision as of 08:58, 10 December 2010
Line 1:		Line 1:
-	<applet load="" size="~~480~~" color="" frame="true" spin="on" Scene ="Lovastatin/Lovastatin/1" align="right" caption="Lovastatin, also known as Mevacor"/>	+	<applet load="" size="[450,380]" color="" frame="true" spin="on" Scene ="Lovastatin/Lovastatin/1" align="right" caption="Lovastatin, also known as Mevacor"/>
	===Better Known as: Mevacor===		===Better Known as: Mevacor===
	* Marketed By: Merck & Co. <br />		* Marketed By: Merck & Co. <br />
Line 13:		Line 13:

	===Pharmacokinetics===		===Pharmacokinetics===
-	~~{\| class~~="~~wikitable" border~~="1" ~~width~~="~~48%~~" ~~style~~="~~text-align:center~~"	+	<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">
-	\|-	+	<tr>
-	~~! colspan~~="7" ~~align="center"\| Statin [[Pharmacokinetics]] at 10mg Dosage.<ref~~>~~PMID:11907637~~<~~/ref~~><~~ref>PMID~~:~~15198967</ref><ref>PMID~~:~~12686673</ref><ref>PMID~~:~~18176327</ref><ref>PMID~~: ~~17452418</ref~~><~~ref>PMID~~:~~12895195</ref>~~	+	<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
-	\|-	+	<div style="height:100%; width: 100%">
-	~~! Parameter~~	+	{{:Statin Pharmacokinetics}}
-	~~! [[Atorvastatin]] (Lipitor)~~	+	</div>
-	~~! [[Fluvastatin]] (Lescol)~~	+	</td>
-	~~! [[Lovastatin]] (Mevacor)~~	+	</tr>
-	~~! [[Simvastatin]] (Zocor)~~	+	</table>
-	~~! [[Rosuvastatin]] (Crestor)~~	+
-	~~! [[Cerivastatin]] (Baycol)~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Tmax\|T<sub>max</sub>]] (hr)~~	+
-	~~! 2.5~~	+
-	~~! 1~~	+
-	~~! 3~~	+
-	~~! 1.5~~	+
-	~~! 4~~	+
-	~~! 1.5~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Cmax\|C<sub>max</sub>]] (ng/ml)~~	+
-	~~! 27-66~~	+
-	~~! 448~~	+
-	~~! 10-20~~	+
-	~~! 7.3~~	+
-	~~! 4.34~~	+
-	~~! 3.43~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Bioavailability_.28F.29\|Bioavailability]] (~~%)	+
-	~~! 12~~	+
-	~~! 19-29~~	+
-	~~! 5~~	+
-	~~! 5~~	+
-	~~! 20~~	+
-	~~! 60~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Protein_Binding\|Protein Binding]] (~~%)	+
-	~~! 80-90~~	+
-	~~! 99~~	+
-	~~! 95~~	+
-	~~! 95~~	+
-	~~! 88~~	+
-	~~! 99~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub~~>~~]] (hr)~~	+
-	~~! 15-30~~	+
-	~~! 2~~	+
-	~~! 3~~	+
-	~~! 2.7~~	+
-	~~! 19~~	+
-	~~! 2.2~~	+
-	\|-	+
-	~~! [[~~Pharmacokinetics~~#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)~~	+
-	~~! 104~~	+
-	~~! ~150~~	+
-	~~! 33~~	+
-	~~! 125~~	+
-	~~! 48~~	+
-	~~! 14.5~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29\|IC<sub>50~~</~~sub~~>~~]] (nM)~~	+
-	~~! 154~~	+
-	~~! 198~~	+
-	~~! 800-4200~~	+
-	~~! 66~~	+
-	~~! 320~~	+
-	~~! 50-90~~	+
-	\|-	+
-	~~! Equivalent LDL Reduction Dosage (mg)~~	+
-	~~! 10~~	+
-	~~! --~~	+
-	~~! 80~~	+
-	~~! 20~~	+
-	~~! 5~~	+
-	~~! --~~	+
-	\|-	+
-	~~! Metabolism~~	+
-	~~! Hepatic~~ <br/>~~(CYP3A4)~~	+
-	~~! Hepatic~~ <br/>~~(CYP2C9)~~	+
-	~~! Hepatic~~ <br/>~~(CYP3A4)~~	+
-	~~! Hepatic <br/>(CYP3A4)~~	+
-	~~! Not <br/>Metabolized~~	+
-	~~! Hepatic <br />(CYP2C8)~~	+
-	\|}	+

	===References===		===References===

David Canner at 15:43, 8 December 2010

David Canner — Wed, 08 Dec 2010 15:43:20 GMT

←Older revision		Revision as of 15:43, 8 December 2010
Line 7:		Line 7:
	* 2000 Sales: $520 Million		* 2000 Sales: $520 Million
	* Importance: Was the first HMG-CoA Inhibitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />		* Importance: Was the first HMG-CoA Inhibitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />
-	* ~~The following is a list of Pharmacokinetic Parameters.~~ See: [[Pharmaceutical Drugs]] for more information	+	* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders

	===Mechanism of Action===		===Mechanism of Action===
Line 15:		Line 15:
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"
	\|-		\|-
-	! colspan="7" align="center"\| Statin [[~~Pharmaceutical_Drugs#Pharmacokinetics_Translated\|~~Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID:12895195</ref>	+	! colspan="7" align="center"\| Statin [[Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID:12895195</ref>
	\|-		\|-
	! Parameter		! Parameter
Line 25:		Line 25:
	! [[Cerivastatin]] (Baycol)		! [[Cerivastatin]] (Baycol)
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Tmax\|T<sub>max</sub>]] (hr)	+	! [[Pharmacokinetics#Tmax\|T<sub>max</sub>]] (hr)
	! 2.5		! 2.5
	! 1		! 1
Line 33:		Line 33:
	! 1.5		! 1.5
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Cmax\|C<sub>max</sub>]] (ng/ml)	+	! [[Pharmacokinetics#Cmax\|C<sub>max</sub>]] (ng/ml)
	! 27-66		! 27-66
	! 448		! 448
Line 41:		Line 41:
	! 3.43		! 3.43
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Bioavailability_.28F.29\|Bioavailability]] (%)	+	! [[Pharmacokinetics#Bioavailability_.28F.29\|Bioavailability]] (%)
	! 12		! 12
	! 19-29		! 19-29
Line 49:		Line 49:
	! 60		! 60
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Protein_Binding\|Protein Binding]] (%)	+	! [[Pharmacokinetics#Protein_Binding\|Protein Binding]] (%)
	! 80-90		! 80-90
	! 99		! 99
Line 57:		Line 57:
	! 99		! 99
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)	+	! [[Pharmacokinetics#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)
	! 15-30		! 15-30
	! 2		! 2
Line 65:		Line 65:
	! 2.2		! 2.2
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)	+	! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)
	! 104		! 104
	! ~150		! ~150
Line 73:		Line 73:
	! 14.5		! 14.5
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)	+	! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)
	! 154		! 154
	! 198		! 198

David Canner at 12:27, 1 December 2010

David Canner — Wed, 01 Dec 2010 12:27:47 GMT

←Older revision		Revision as of 12:27, 1 December 2010
Line 6:		Line 6:
	* Date of FDA Approval (Patent Expiration): 1991 (2001)<br />		* Date of FDA Approval (Patent Expiration): 1991 (2001)<br />
	* 2000 Sales: $520 Million		* 2000 Sales: $520 Million
-	* ~~Why You Should Care~~: Was the first HMG-CoA Inhibitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />	+	* Importance: Was the first HMG-CoA Inhibitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />
	* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information		* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
		+
	===Mechanism of Action===		===Mechanism of Action===
	Lovastatin is rapidly hydrolyzed in vivo into its corresponding b-hydroxyacid, which is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>		Lovastatin is rapidly hydrolyzed in vivo into its corresponding b-hydroxyacid, which is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>

David Canner at 18:26, 29 November 2010

David Canner — Mon, 29 Nov 2010 18:26:02 GMT

←Older revision		Revision as of 18:26, 29 November 2010
Line 14:		Line 14:
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"
	\|-		\|-
-	! colspan="6" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] at 10mg Dosage. <ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID: ~~11907637~~</ref>	+	! colspan="7" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID:12895195</ref>
	\|-		\|-
	! Parameter		! Parameter
Line 22:		Line 22:
	! [[Simvastatin]] (Zocor)		! [[Simvastatin]] (Zocor)
	! [[Rosuvastatin]] (Crestor)		! [[Rosuvastatin]] (Crestor)
		+	! [[Cerivastatin]] (Baycol)
	\|-		\|-
	! [[Pharmaceutical_Drugs#Tmax\|T<sub>max</sub>]] (hr)		! [[Pharmaceutical_Drugs#Tmax\|T<sub>max</sub>]] (hr)
Line 29:		Line 30:
	! 1.5		! 1.5
	! 4		! 4
		+	! 1.5
	\|-		\|-
	! [[Pharmaceutical_Drugs#Cmax\|C<sub>max</sub>]] (ng/ml)		! [[Pharmaceutical_Drugs#Cmax\|C<sub>max</sub>]] (ng/ml)
Line 35:		Line 37:
	! 10-20		! 10-20
	! 7.3		! 7.3
-	!4.34	+	! 4.34
		+	! 3.43
	\|-		\|-
	! [[Pharmaceutical_Drugs#Bioavailability_.28F.29\|Bioavailability]] (%)		! [[Pharmaceutical_Drugs#Bioavailability_.28F.29\|Bioavailability]] (%)
Line 43:		Line 46:
	! 5		! 5
	! 20		! 20
		+	! 60
	\|-		\|-
	! [[Pharmaceutical_Drugs#Protein_Binding\|Protein Binding]] (%)		! [[Pharmaceutical_Drugs#Protein_Binding\|Protein Binding]] (%)
Line 50:		Line 54:
	! 95		! 95
	! 88		! 88
		+	! 99
	\|-		\|-
	! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)		! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)
Line 57:		Line 62:
	! 2.7		! 2.7
	! 19		! 19
		+	! 2.2
	\|-		\|-
	! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)		! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)
Line 64:		Line 70:
	! 125		! 125
	! 48		! 48
		+	! 14.5
	\|-		\|-
	! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)		! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)
Line 71:		Line 78:
	! 66		! 66
	! 320		! 320
		+	! 50-90
	\|-		\|-
	! Equivalent LDL Reduction Dosage (mg)		! Equivalent LDL Reduction Dosage (mg)
Line 78:		Line 86:
	! 20		! 20
	! 5		! 5
		+	! --
	\|-		\|-
	! Metabolism		! Metabolism
Line 85:		Line 94:
	! Hepatic <br/>(CYP3A4)		! Hepatic <br/>(CYP3A4)
	! Not <br/>Metabolized		! Not <br/>Metabolized
		+	! Hepatic <br />(CYP2C8)
	\|}		\|}
		+
	===References===		===References===
	<references/>		<references/>
	__NOEDITSECTION__		__NOEDITSECTION__
	__NOTOC__		__NOTOC__

David Canner at 18:07, 29 November 2010

David Canner — Mon, 29 Nov 2010 18:07:57 GMT

←Older revision		Revision as of 18:07, 29 November 2010
Line 1:		Line 1:
-	<applet load="" size="480" color="" frame="true" spin="on" Scene ="~~Fluvastatin~~/~~Fluvastatin~~/1" align="right" caption="~~Fluvastatin~~, also known as ~~Lescol~~"/>	+	<applet load="" size="480" color="" frame="true" spin="on" Scene ="Lovastatin/Lovastatin/1" align="right" caption="Lovastatin, also known as Mevacor"/>
	===Better Known as: Mevacor===		===Better Known as: Mevacor===
	* Marketed By: Merck & Co. <br />		* Marketed By: Merck & Co. <br />

David Canner at 18:05, 29 November 2010

David Canner — Mon, 29 Nov 2010 18:05:40 GMT

←Older revision		Revision as of 18:05, 29 November 2010
Line 9:		Line 9:
	* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information		* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
	===Mechanism of Action===		===Mechanism of Action===
-	Lovastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>	+	Lovastatin is rapidly hydrolyzed in vivo into its corresponding b-hydroxyacid, which is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>

	===Pharmacokinetics===		===Pharmacokinetics===

David Canner at 18:03, 29 November 2010

David Canner — Mon, 29 Nov 2010 18:03:39 GMT

←Older revision		Revision as of 18:03, 29 November 2010
Line 6:		Line 6:
	* Date of FDA Approval (Patent Expiration): 1991 (2001)<br />		* Date of FDA Approval (Patent Expiration): 1991 (2001)<br />
	* 2000 Sales: $520 Million		* 2000 Sales: $520 Million
-	* Why You Should Care: Was ~~largely replaced by [[Lipitor]]~~. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />	+	* Why You Should Care: Was the first HMG-CoA Inhibitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />
	* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information		* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
	===Mechanism of Action===		===Mechanism of Action===
-	Lovastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. ~~Fluvastatin~~ outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>	+	Lovastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>

	===Pharmacokinetics===		===Pharmacokinetics===

David Canner at 18:01, 29 November 2010

David Canner — Mon, 29 Nov 2010 18:01:04 GMT

←Older revision		Revision as of 18:01, 29 November 2010
Line 1:		Line 1:
	<applet load="" size="480" color="" frame="true" spin="on" Scene ="Fluvastatin/Fluvastatin/1" align="right" caption="Fluvastatin, also known as Lescol"/>		<applet load="" size="480" color="" frame="true" spin="on" Scene ="Fluvastatin/Fluvastatin/1" align="right" caption="Fluvastatin, also known as Lescol"/>
-	===Better Known as: ~~Lescol~~===	+	===Better Known as: Mevacor===
-	* Marketed By: ~~Novartis~~ <br />	+	* Marketed By: Merck & Co. <br />
	* Major Indication: Hyperlipidemia & High Cholesterol ([[Metabolic Disorders\|Hypercholesterolemia]])<br />		* Major Indication: Hyperlipidemia & High Cholesterol ([[Metabolic Disorders\|Hypercholesterolemia]])<br />
	* Drug Class: [[HMGR]] Inhibitor or Statin		* Drug Class: [[HMGR]] Inhibitor or Statin
-	* Date of FDA Approval (Patent Expiration): ~~1993~~ (~~2011~~)<br />	+	* Date of FDA Approval (Patent Expiration): 1991 (2001)<br />
-	* 2000 Sales: $~~430~~ Million	+	* 2000 Sales: $520 Million
	* Why You Should Care: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />		* Why You Should Care: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />
	* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information		* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
	===Mechanism of Action===		===Mechanism of Action===
-	~~Fluvastatin~~ is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Fluvastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>	+	Lovastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Fluvastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>

	===Pharmacokinetics===		===Pharmacokinetics===

David Canner at 17:59, 29 November 2010

David Canner — Mon, 29 Nov 2010 17:59:05 GMT

←Older revision		Revision as of 17:59, 29 November 2010
Line 74:		Line 74:
	! Equivalent LDL Reduction Dosage (mg)		! Equivalent LDL Reduction Dosage (mg)
	! 10		! 10
-	!	+	! --
	! 80		! 80
	! 20		! 20